United States

People: Jounce Therapeutics Inc (JNCE.OQ)

JNCE.OQ on NASDAQ Stock Exchange Global Select Market

2:54pm EDT
Change (% chg)

$0.37 (+4.67%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Trehu, Elizabeth 

Dr. Elizabeth G. Trehu, M.D. is the Chief Medical Officer of the Company. Dr. Trehu joined Jounce as our chief medical officer in November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc. from 2012 to 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010, vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. Previously, Dr. Trehu served from 2002 to 2006 in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.

Basic Compensation

Total Annual Compensation, USD 534,000
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 302,910
Fiscal Year Total, USD 836,910

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --